Art. -Nr.: HY-10095A

Olcegepant hydrochloride

(Synonyms: BIBN-4096 hydrochloride; BIBN4096BS hydrochloride)

45 Cited Publications

Kundenbewertung

Based on 45 publication(s) in Google Scholar

Olcegepant hydrochloride (BIBN-4096 hydrochloride) is a potent and selective non-peptide antagonist of the calcitonin gene-related peptide 1 (CGRP1) receptor with IC₅₀ of 0.03 nM and with a K_i of 14.4 pM for human CGRP.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.69%
CAS. Nr.: 586368-06-1
Formel: C₃₈H₄₇Br₂N₉O₅.HCl
Molecular Weight:906.11

Speicherung:

4°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Olcegepant hydrochloride Chemical Structure

CAS. Nr.: 586368-06-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (45)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 0.03 nM (CGRP1)^[1]
Ki: 14.4 pM (hCGRP)^[2]

In Vitro

Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37. Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology^[1]. Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (K_i) for human CGRP receptors of 14.4±6.3 (n=4) pM^[2]. Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a novel abortive migraine treatment. Olcegepant (BIBN4096BS) exhibits competitive antagonism at the CGRP receptor present in SK-N-MC cells. Isolated human cerebral, coronary, and omental arteries are studied with a sensitive myograph technique. CGRP induces a concentration-dependent relaxation that is antagonized by Olcegepant in a competitive manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Olcegepant (BIBN4096BS) in doses between 1 and 30 μg/kg (i.v.) inhibits the effects of CGRP, released by stimulation of the trigeminal ganglion, on facial blood flow in marmoset monkeys^[2]. Pre-treatment with Olcegepant (900 μg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%. In contrast, the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment^[4]. Olcegepant (0.3 to 0.9 mg/kg, i.v.) markedly reduces mechanical allodynia in CCI-ION rats. Olcegepant (0.6 mg/kg, i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 586368-06-1
Appearance Solid
Molecular Weight 906.11
Formel C₃₈H₄₇Br₂N₉O₅.HCl
Color Off-white to yellow
SMILES

O=C1N(CC2=C(N1)C=CC=C2)C3CCN(C(N[C@@H](C(N[C@H](C(N4CCN(C5=CC=NC=C5)CC4)=O)CCCCN)=O)CC6=CC(Br)=C(C(Br)=C6)O)=O)CC3.Cl
Synonyms

BIBN-4096 hydrochloride; BIBN4096BS hydrochloride
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Publications (45)

All In Vivo Efficacy StudyFlow CytometryELISAHistological Imaging/Staining

Sort by:

Journal Impact Factor

Nat Med

Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats. [Abstract]

2016 Oct;22(10):1160-1169. PMID: 27571347

Olcegepant hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Med. 2016 Oct;22(10):1160-1169. [Abstract]

In vivo imaging (by IVIS200 system) of different organs in a rat 2 weeks after injections of Cy5‐labeled Olcegepant (BIBN4096BS, BIBN, 750 µg/mL, 100 µL, pH 6.0, every other day) , a CGRP receptor antagonist, into left femur.
Cell

Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer. [Abstract]

2026 May 19:S0092-8674(26)00505-2. PMID: 42161272
Cell

Innervation of nociceptor neurons in the spleen promotes germinal center responses and humoral immunity. [Abstract]

2024 Jun 6;187(12):2935-2951.e19. PMID: 38772371

Olcegepant hydrochloride purchased from MedChemExpress. Usage Cited in: Cell. 2024 Jun 6;187(12):2935-2951.e19. [Abstract]

Representative pseudocolor plots (L) and summary data (M) of proportions of splenic GC B cells and SPPCs 13 days after NP-KLH immunization in mice i.p. injected with vehicle or Olcegepant (BIBN4096, 5 mg/kg) every other day. n = 17 mice per group.

Olcegepant hydrochloride purchased from MedChemExpress. Usage Cited in: Cell. 2024 Jun 6;187(12):2935-2951.e19. [Abstract]

ELISA titration curves of NP-specific IgG antibodies on day 13 post NP-KLH immunization in mice i.p. injected with vehicle or Olcegepant (BIBN4096, 5 mg/kg) every other day. n = 12 mice per group.
Adv Sci (Weinh)

Bioinspired Engineering of Streamlined Skeletal Interoception: Neural Bioprinted Piezoelectric Scaffolds for Neuro-Vascularized Bone Regeneration. [Abstract]

2026 Apr;13(21):e24181. PMID: 41691467
Adv Sci (Weinh)

Staphylococcus Aureus Tames Nociceptive Neurons to Suppress Synovial Macrophage Responses for Sustained Infection in Septic Arthritis. [Abstract]

2025 Apr;12(14):e2409251. PMID: 39960341

Olcegepant hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2409251. [Abstract]

Typical micro‐CT images of knee joints on the 28th day after S. aureus infection in vehicle and Olcegepant (BIBN4096, 5 µg/5 µL; intra-articular injection into the knee joint 2 h before infection; once weekly) treated mice (left) and the differences in tibial epiphyseal volume between the two groups (right). n = 5 mice/group. (Scale bar: 500 µm).

Olcegepant hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Apr;12(14):e2409251. [Abstract]

Olcegepant (BIBN4096, 5 µg/5 µL; intra-articular injection into the knee joint 2 h before infection; once weekly).
Typical H&E-stained images of knee joints (left) and scores based on H&E staining that show differences in synovial and bone damage between the two groups on the 28th day after S. aureus infection (right). n = 8 mice/group (Scale bar: 500 µm).
Adv Sci (Weinh)

Sensory Nerve Regulation via H3K27 Demethylation Revealed in Akermanite Composite Microspheres Repairing Maxillofacial Bone Defect. [Abstract]

2024 Aug;11(30):e2400242. PMID: 38874525
Adv Sci (Weinh)

Implantable Electrical Stimulation at Dorsal Root Ganglions Accelerates Osteoporotic Fracture Healing via Calcitonin Gene-Related Peptide. [Abstract]

2021 Oct 28;e2103005. PMID: 34708571
J Orthop Translat

Talin1 loss activates DRG neurons to accelerate bone remodeling and fracture healing in mice. [Abstract]

2026 May 8:58:101113. PMID: 42169959
Small Methods

Wireless Optogenetic Targeting Nociceptors Helps Host Cells Win the Competitive Colonization in Implant-Associated Infections. [Abstract]

2024 Dec;8(12):e2400216. PMID: 39087367
J Headache Pain

Differential expression of components of the CGRP-receptor family in human coronary and human middle meningeal arteries: functional implications. [Abstract]

2024 Oct 10;25(1):176. PMID: 39390360
J Headache Pain

Brain-wide mapping of c-Fos expression in nitroglycerin-induced models of migraine. [Abstract]

2024 Aug 21;25(1):136. PMID: 39169303
J Headache Pain

A c-Fos activation map in nitroglycerin/levcromakalim-induced models of migraine. [Abstract]

2022 Sep 30;23(1):128. PMID: 36180824
J Headache Pain

Calcitonin gene-related peptide receptor antagonist BIBN4096BS regulates synaptic transmission in the vestibular nucleus and improves vestibular function via PKC/ERK/CREB pathway in an experimental chronic migraine rat model. [Abstract]

2022 Mar 8;23(1):35. PMID: 35260079
Cell Rep

SETDB2-mediated transcriptional repression of IDE in sensory neurons promotes migraine-like pain behaviors in mice. [Abstract]

2026 Mar 24;45(4):117201. PMID: 41880325
Cell Rep

ILC2-derived CGRP triggers acute inflammation and nociceptive responses in bacterial cystitis. [Abstract]

2024 Oct 15;43(10):114859. PMID: 39412984
Br J Pharmacol

Naringenin relieves paclitaxel-induced pain by suppressing calcitonin gene-related peptide signalling and enhances the anti-tumour action of paclitaxel. [Abstract]

2024 Sep;181(17):3136-3159. PMID: 38715438
J Invest Dermatol

Thromboxane-Induced α-CGRP Release from Peripheral Neurons Is an Essential Positive Feedback Loop in Capsaicin-Induced Neurogenic Inflammation. [Abstract]

2019 Mar;139(3):656-664. PMID: 30612974
Biochem Pharmacol

Calcitonin gene-related peptide/protein kinase A: A novel pathway to regulate patency of ductus arteriosus. [Abstract]

2026 Jun:248:117840. PMID: 41724283
Cell Mol Life Sci

Sensory nerves drive migration of dental pulp stem cells via the CGRP-Ramp1 axis in pulp repair. [Abstract]

2024 Aug 28;81(1):373. PMID: 39196292
Int Endod J

Sensory nerves, but not sympathetic nerves, promote reparative dentine formation after dentine injury via CGRP-mediated angiogenesis: An in vivo study. [Abstract]

2024 Jan;57(1):37-49. PMID: 37874659
Cephalalgia

Sex differences in CGRP-induced vasodilation of human middle meningeal arteries but not human coronary arteries: implications for migraine. [Abstract]

2024 Jul;44(7):3331024241254088. PMID: 39043230
Cephalalgia

No additive effect of combining sumatriptan and olcegepant in the GTN mouse model of migraine. [Abstract]

2021 Mar;41(3):329-339. PMID: 33059476
Cephalalgia

No central action of CGRP antagonising drugs in the GTN mouse model of migraine. [Abstract]

2020 Aug;40(9):924-934. PMID: 32223300
Cephalalgia

Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. [Abstract]

2019 Dec;39(14):1827-1837. PMID: 31288556
Int Immunopharmacol

Calcitonin gene-related peptide-modulated macrophage phenotypic alteration regulates angiogenesis in early bone healing. [Abstract]

2024 Mar 30:130:111766. PMID: 38452411
Int J Mol Sci

CGRP Signaling via CALCRL Increases Chemotherapy Resistance and Stem Cell Properties in Acute Myeloid Leukemia. [Abstract]

2019 Nov 20;20(23):5826. PMID: 31756985
Invest Ophthalmol Vis Sci

Corneal Nerves Promote Alkali Burn Repair by Modulating Macrophages and Neutrophils via Calcitonin Gene-Related Peptide. [Abstract]

2026 Apr 1;67(4):60. PMID: 42041175
Invest Ophthalmol Vis Sci

CGRP/TSP1 Signaling Dampens Corneal Inflammation and Fibrosis by Targeting A2M During Corneal Stromal Wound Healing. [Abstract]

2026 Jan 5;67(1):10. PMID: 41533912
Sci Rep

Peripheral N-methyl-D-aspartate receptor activation contributes to monosodium glutamate-induced headache but not nausea behaviours in rats. [Abstract]

2022 Aug 16;12(1):13894. PMID: 35974090
Sci Rep

Cortical spreading depolarisation-induced facial hyperalgesia, photophobia and hypomotility are ameliorated by sumatriptan and olcegepant. [Abstract]

2020 Jul 10;10(1):11408. PMID: 32651400
Sci Rep

A unique inbred rat strain with sustained cephalic hypersensitivity as a model of chronic migraine-like pain. [Abstract]

2018 Jan 30;8(1):1836. PMID: 29382888
Front Cell Neurosci

Paralogs of the Calcium-Dependent Activator Protein for Secretion Differentially Regulate Synaptic Transmission and Peptide Secretion in Sensory Neurons. [Abstract]

2018 Sep 11:12:304. PMID: 30254567
Korean J Pain

Anti-nociceptive effects of dual neuropeptide antagonist therapy in mouse model of neuropathic and inflammatory pain. [Abstract]

2022 Apr 1;35(2):173-182. PMID: 35354680
Vascul Pharmacol

Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. [Abstract]

2017 Mar:90:36-43. PMID: 28192258
Peptides

Neuronal calcitonin gene-related peptide promotes prostate tumor growth in the bone microenvironment. [Abstract]

2021 Jan:135:170423. PMID: 33086087
Tissue Cell

Sensory neuron TRPV1-mediated macrophage polarization and immune response regulate dental implant osseointegration. [Abstract]

2026 Apr:99:103243. PMID: 41297248
Biomed Res Int

Neural Peptide α-CGRP Coregulated Angiogenesis and Osteogenesis via Promoting the Cross-Talk between Mesenchymal Stem Cells and Endothelial Cells. [Abstract]

2022 Jun 16;2022:1585840. PMID: 35757476
Orthop J Sports Med

Calcitonin Gene-Related Peptide Influences Bone-Tendon Interface Healing Through Osteogenesis: Investigation in a Rabbit Partial Patellectomy Model. [Abstract]

2021 Jul 13;9(7):23259671211003982. PMID: 34345631
Neuropeptides

Periodontal CGRP contributes to orofacial pain following experimental tooth movement in rats. [Abstract]

2015 Aug:52:31-7. PMID: 26164378
Cell Physiol Biochem

NPY and CGRP Inhibitor Influence on ERK Pathway and Macrophage Aggregation during Fracture Healing. [Abstract]

2017;41(4):1457-1467. PMID: 28315869
Biomed Pharmacother

α6GABAA receptor positive allosteric modulators targeting trigeminal ganglia for preventing and aborting chronic periorbital allodynia and cephalic pain in both sexes: A mechanistic and comparative preclinical study. [Abstract]

2025 Aug:189:118344. PMID: 40652726
Research Square Print

August 19th, 2022.
J Tradit Chinese Medical Sci

21 June 2022.
Freie Universitt Berlin

2021 Feb.
Department of Biology, Chemistry, Pharmacy

2020 Oct.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (110.36 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 66.66 mg/mL (73.57 mM)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1036 mL

5.5181 mL

11.0362 mL

5 mM

0.2207 mL

1.1036 mL

2.2072 mL

10 mM

0.1104 mL

0.5518 mL

1.1036 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Kinase Assay^[2]

¹²⁵I-hCGRP is used as the radioligand. The incubation buffer contained (in mM): Tris 50, NaCl 150, MgCl₂ 5 and EDTA 1, (ethylene diamine tetra-acetic acid) pH 7.4. Membrane homogenates are incubated for 180 min at room temperature with 50 pM ¹²⁵I -hCGRP and increasing concentrations of Olcegepant (BIBN4096BS). The incubation is terminated by filtration through GF/B glass fibre filters using a cell harvester. The protein-bound radioactivity is determined in a gamma counter. The nonspecific binding is defined as radioactivity bound in the presence of 1 μM CGRP. The IC₅₀ values are obtained by non-linear regression analysis on the basis of a one binding site model ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[3]

Cells are washed with phosphate-buffered saline then pre-incubated with 300 μM isobutylmethylxanthine in serum-free MEM for 30 min at 37 °C α-CGRP-(S-37) or Olcegepant (BIBN4096BS) is added and the cells are incubated for 10 min before the addition of CGRP. The incubation is continued for another 15 min, then the cells are washed with PBS and processed for cAMP determination. Maximal stimulation over basal is defined by using 100 nM CGRP. Dose–response curves are generated by using Prism^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[5]

Rats are treated acutely with Olcegepant (0.3, 0.6, and 0.9 mg/kg, intravenously [i.v.] in a tail vein), GR-85548A (0.1 and 0.3 mg/kg subcutaneously [s.c.]), or their respective vehicle. For combined treatment, Olcegepant (0.3 mg/kg, i.v.) is administered 30 minutes before GR-85548A (0.1 mg/kg, s.c.). The doses and routes of administration are based on previous reports.
For subchronic treatment, CCI-ION and sham-operated rats are injected twice per day for 4 days (at 10 am and 6 pm) with Olcegepant (0.6 mg/kg, i.v.) or its vehicle, starting on the 15th day after ligature. A further injection of Olcegepant (0.6 mg/kg, i.v.) or vehicle is performed at 10 am the subsequent day (19th day after ligature), just before von Frey filament testing.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rudolf K, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem. 2005 Sep 22;48(19):5921-31. [Content Brief]

[2]. Edvinsson L, et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omentalarteries and in SK-N-MC cells. Eur J Pharmacol. 2002 Jan 2;434(1-2):49-53. [Content Brief]

[3]. Doods H, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000 Feb;129(3):420-3. [Content Brief]

[4]. Sixt ML, et al. Calcitonin gene-related peptide receptor antagonist Olcegepant acts in the spinal trigeminal nucleus. Brain. 2009 Nov;132(Pt 11):3134-41. [Content Brief]

[5]. Michot B, et al. Differential effects of calcitonin gene-related peptide receptor blockade by Olcegepant on mechanical allodynia induced by ligation of the infraorbital nerve vs the sciatic nerve in the rat. Pain. 2012 Sep;153(9):1939-48. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.1036 mL	5.5181 mL	11.0362 mL	27.5905 mL
	5 mM	0.2207 mL	1.1036 mL	2.2072 mL	5.5181 mL
	10 mM	0.1104 mL	0.5518 mL	1.1036 mL	2.7590 mL
	15 mM	0.0736 mL	0.3679 mL	0.7357 mL	1.8394 mL
	20 mM	0.0552 mL	0.2759 mL	0.5518 mL	1.3795 mL
	25 mM	0.0441 mL	0.2207 mL	0.4414 mL	1.1036 mL
	30 mM	0.0368 mL	0.1839 mL	0.3679 mL	0.9197 mL
	40 mM	0.0276 mL	0.1380 mL	0.2759 mL	0.6898 mL
	50 mM	0.0221 mL	0.1104 mL	0.2207 mL	0.5518 mL
	60 mM	0.0184 mL	0.0920 mL	0.1839 mL	0.4598 mL
DMSO	80 mM	0.0138 mL	0.0690 mL	0.1380 mL	0.3449 mL
DMSO	100 mM	0.0110 mL	0.0552 mL	0.1104 mL	0.2759 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Olcegepant hydrochloride

45 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Olcegepant hydrochloride

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

Publications Citing Use of MedChemExpress (MCE) Olcegepant hydrochloride

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Olcegepant hydrochloride

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

Publications Citing Use of MedChemExpress (MCE) Olcegepant hydrochloride

Biologische Aktivität

Chemical Information

Publications (45)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Olcegepant hydrochloride Related Classifications

HY-10095A Related Classifications